X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Insights

Tycko & Zavareei LLP Scores Appellate Victory on Behalf of APA Membership

Yuvraj_pawp by Yuvraj_pawp
5th September 2014
in Insights

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Tycko & Zavareei has scored a significant appellate victory on behalf of the membership of the American Psychological Association (“APA”). On September 5, 2014, the United States Court of Appeals for the D.C. Circuit reversed the trial court’s dismissal of a class action complaint alleging improper dues-charging practices by the APA, in Levine et al. v. American Psychological Association and American Psychological Association Practice Organization. The decision was authored by Circuit Judge Sri Srinivasan on behalf of a unanimous panel that also included Circuit Judges Judith Rogers and Thomas Griffith.

 

In their class action complaint, members of the APA—represented by Tycko & Zavareei—alleged that the APA falsely represented to its members (on its annual dues statements and elsewhere) that they were required to pay an annual “practice assessment” for continued APA membership. According to the lawsuit, payment of the assessment was not, in fact, a condition of APA membership. Rather, the APA funneled these funds to its lobbying arm: the American Psychological Association Practice Organization (“APAPO”). The plaintiffs asserted that the APA did this because it did not believe that its members would voluntarily donate sufficient funds to the APAPO to support its lobbying activities; however, it could not mandate payment of funds for lobbying purposes as a condition of membership without jeopardizing its tax-exempt status as a 501(c)(3) charitable organization under the Internal Revenue Code. Thus, the APA allegedly tried to have it both ways: by falsely representing in its communications to its members that payment of the practice assessment was a condition of APA membership to obtain funding for the APAPO, but not making payment of the assessment an official membership requirement to avoid potentially losing its federal tax-exempt status.

 

The D.C. Circuit disagreed with the trial court’s conclusion that the plaintiffs failed to state viable legal claims. Namely, the court reversed the dismissal of claims against the APA for unjust enrichment and also disagreed with the trial court’s conclusion that the plaintiffs could not amend their complaint to state a claim for fraudulent inducement on the grounds that any amendment could be futile. Finally, the D.C. Circuit held that the plaintiffs were free to move for leave to amend their complaint to add a cause of action for negligent misrepresentation.

 

In its decision, the D.C. Circuit held that plaintiffs adequately alleged that the APA “included misleading language on the dues statement in order to deceive plaintiffs into overpaying for APA membership.” In assessing the case, the court observed that “the dues statement contained several indications that payment of the special assessment was a requirement of APA membership.” The court also observed that in light of plaintiffs’ allegations that the APA website did not allow payment of dues without payment of the special assessment, “[a] member who viewed the dues statement in conjunction with the website therefore had even greater reason to believe that payment of the special assessment was a condition of APA membership.” In the face of the APA’s contention that despite the misleading language on the dues statements, plaintiffs should have investigated further before paying what they thought was required, the D.C. Circuit panel disagreed, stating that “plaintiffs reasonably could have concluded that the meaning of the dues statement was clear, such that there was no reason to investigate further.”

 

Lead attorney for the plaintiffs, Hassan Zavareei, explained, “This decision by the DC Circuit establishes the basis for a nationwide class against the APA for its deceptive charges of its own members. We are pleased that the case can now proceed so that we can seek restitution for the thousands of psychologists who were duped into paying hundreds of dollars for controversial lobbying efforts by the APA lobbying entity.” The case will now be remanded to the United States District Court for the District of Columbia for further proceedings. The plaintiffs were also represented by Wexler Wallace, LLP, Miller Law Firm, P.C., Greg Coleman Law PC, and Whitfield Bryson & Mason LLP. In addition, Tycko & Zavareei represents the plaintiff in a related class action, Grossman v. American Psychological Association and American Psychological Association Practice Organization.

SOURCE Tycko & Zavareei LLP

Previous Post

Luye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical

Next Post

Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

Related Posts

Role of CDMOs In Technology Transfer From Molecule To Market
Insights

Role of CDMOs In Technology Transfer From Molecule To Market

19th June 2025
CDMOs Driving Agile Production Within Intricate Therapies
Insights

CDMOs Driving Agile Production Within Intricate Therapies

19th June 2025
Regulatory Trends in Pharma
Insights

Regulatory Trends in Pharma Manufacturing to Watch in 2025

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Insights

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

27th May 2025
Capsules Market
Insights

Empty Capsules Market Growth to Reach $4.2B by 2029

16th April 2025
Next Post

Phase Holographic Imaging Announces Collaboration Agreement with Northeastern University

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In